Mutations in the epidermal growth factor receptor (EGFR) are among the most common activating mutations in non-small cell lung cancer (NSCLC), with exon 19 deletions (ex19del) and exon 21 L858R mutations accounting for approximately 85–90% of all cases1,2. Here, EGFR is linked to non-small cell lung carcinoma.